Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052350 | 1.00 | KDM1A (0.48) | KDM1AAKR1C3HSD11B1ACHEHTR1B | |
| SCHEMBL8254274 | 1.00 | KDM1A (0.48) | KDM1AAKR1C3HSD11B1ACHEHTR1B | |
| SCHEMBL15437821 | 0.90 | KDM1A (0.46) | KDM1AAKR1C3HSD11B1ACHEHTR1B | |
| SCHEMBL13550403 | 0.86 | ALDH1A1 (0.49) | KDM1AAKR1C3ACHE | |
| SCHEMBL8189658 | 0.86 | ALDH1A1 (0.49) | KDM1AAKR1C3ACHE | |
| SCHEMBL785696 | 0.86 | ALDH1A1 (0.49) | KDM1AAKR1C3ACHE | |
| SCHEMBL15630855 | 0.85 | NPC1 (0.47) | ACHEDRD3DRD2 | |
| Hydrochloric Acid SCHEMBL785877 | 0.85 | ALDH1A1 (0.47) | KDM1AAKR1C3ACHE | |
| SCHEMBL8256333 | 0.81 | AKR1C3 (0.48) | KDM1AAKR1C3HSD11B1PARP1TSHR | |
| SCHEMBL10164087 | 0.81 | AKR1C3 (0.48) | KDM1AAKR1C3HSD11B1PARP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874993-B1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma AG (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-9387203-B2 | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150174113-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | US | disclosed |
| CN-104703964-A | Substituted aminoindane- and aminotetralincarboxylic acids and use thereof | Bayer Pharma AG | 2015-06-10 | — | — | CN | disclosed |
| EP-2874993-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINCARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014012935-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINCARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-23 | — | — | WO | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174113-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF | AADAT, DDC, AASDHPPT | KDM1A 3614/4885AKR1C3 989/4885HSD11B1 793/4885 |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | KDM1A 2508/4885AKR1C3 2288/4885HSD11B1 2052/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | KDM1A 2508/4885AKR1C3 2288/4885HSD11B1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.